Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Multiple Myeloma 186Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 41Recurrence 28Neoplasms, Plasma Cell 27Lymphoma 25Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 20Lymphoma, B-Cell, Marginal Zone 15Lymphoma, Non-Hodgkin 14Leukemia, Myeloid, Acute 13Smoldering Multiple Myeloma 9Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 7Lymphoma, B-Cell 7Waldenstrom Macroglobulinemia 6Neoplasms 6Neoplasm, Residual 6Immunoglobulin Light-chain Amyloidosis 6Lymphoma, T-Cell 5Leukemia, Plasma Cell 5Leukemia, Myelomonocytic, Chronic 5Renal Insufficiency 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Hematologic Diseases 4Sezary Syndrome 3

Interventions

Darbepoetin alfa 19Epoetin Alfa 17ACE-011 4Cyclosporine 3Busulfan 3luspatercept 2fludarabine phosphate 2fludarabine 2ferric carboxymaltose 2epoetin beta 2continuous erythropoietin receptor activator 2Methotrexate 2Iron-Dextran Complex 2Filgrastim 2Cyclophosphamide 2vactosertib 1thymoglobulin 1ruxolitinib 1roxadustat 1peginesatide 1pegfilgrastim 1niraparib 1leridistim 1iron isomaltoside 1000 1hematide 1ferric gluconate 1eltrombopag 1angiotensin I (1-7) 1Therapeutics 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia × Lenalidomide × Clear all
NCT01772420 2023-07-27

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Albert Einstein College of Medicine

Phase 2 Completed
52 enrolled 21 charts
Classical hematologyOther hematologic neoplasm

Anemia, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡